How Transdermal Patches Deliver Medication Through Skin

A transdermal patch delivers medication through the skin and directly into the bloodstream, bypassing the digestive system entirely. This avoids the so-called first-pass effect, where the liver breaks down a large share of an oral drug before it ever reaches circulation, and also sidesteps the acidic environment of the stomach that can degrade certain molecules.¹ The concept sounds simple, but the science behind getting a drug molecule through skin, keeping it there at the right rate, and doing so safely involves a surprising amount of engineering and biology.

How a Drug Gets Through Skin

Skin is an extraordinarily good barrier. The outermost layer, the stratum corneum, is only about 10 to 20 micrometers thick, but it is dense with tightly packed lipid bilayers that block most foreign molecules from passing through. This barrier is so effective that only very potent drugs administered in small doses have historically been viable for transdermal delivery.² A drug molecule sitting on the skin surface has to dissolve into and diffuse through these lipid layers to reach the tiny blood vessels underneath.

To help drugs get through, patch formulations often include chemical penetration enhancers. These substances work by disrupting the organized lipid structure of the stratum corneum, either by extracting some of those lipids or by making the bilayers more fluid and disordered.³ Think of it like loosening the mortar between bricks: the wall is still there, but gaps form that molecules can squeeze through. Certain phospholipids, for instance, increase the fluidity of these skin lipid bilayers, which allows more drug to partition into the skin from the patch.

Not every drug can make this journey. The molecule has to be small enough to diffuse through, lipophilic enough to enter the fatty lipid layers, and potent enough that a therapeutic dose can be delivered through the limited surface area of a patch. Molecular weight, solubility, and the balance between fat- and water-loving properties all determine whether a drug is even a candidate for transdermal delivery. Skin hydration, local temperature, and which body region the patch sits on all influence how much drug ultimately makes it through.

What Drugs Are Currently Delivered by Patch

Given these strict physicochemical requirements, the list of drugs with FDA-approved transdermal formulations is relatively short but spans several medical areas. Chronic pain management uses fentanyl and buprenorphine patches. Neurological conditions are treated with rotigotine (for Parkinson’s disease) and rivastigmine (for Alzheimer’s dementia). Cardiovascular applications include nitroglycerin patches for angina and clonidine patches for hypertension. Hormone replacement therapy relies on estradiol patches (sometimes combined with progestin). And nicotine patches remain one of the most widely recognized examples, used for smoking cessation.⁴ Scopolamine patches for motion sickness and testosterone patches for hormone therapy round out the roster.

What unites all these drugs is that they are effective at very low blood concentrations, their molecules are small and lipophilic enough to cross skin, and the conditions they treat benefit from steady, sustained drug levels rather than the peaks and valleys of oral dosing. A fentanyl patch, for example, delivers a continuous low dose over 72 hours, which helps maintain pain control without the concentration spikes that contribute to side effects and misuse risk with oral opioids.

Matrix Patches Versus Reservoir Patches

The two main patch designs handle drug storage and release differently, and the distinction matters more than most patients realize. A matrix patch embeds the drug throughout an adhesive or polymer layer. As the patch sits on skin, the drug diffuses out of this matrix and into the stratum corneum. A reservoir patch, by contrast, holds the drug in a liquid or gel compartment separated from the skin by a rate-controlling membrane. That membrane governs how fast the drug reaches the skin surface.

Under normal conditions, the two designs tend to deliver comparable amounts of drug. In studies of fentanyl patches applied to intact skin at normal skin temperature, reservoir and matrix systems produced similar permeation profiles.⁵ But the designs diverge under stress. When skin is partially compromised, such as from abrasion or a skin condition, a matrix patch actually shows greater permeation enhancement than a reservoir patch, because the reservoir’s rate-limiting membrane continues to restrict how fast the drug can move even when skin permeability increases. That built-in membrane acts as a safety brake, which is a meaningful advantage for potent drugs like fentanyl when skin integrity cannot be guaranteed.

Estradiol patches tell a similar story from a different angle. In a comparison of matrix and reservoir estradiol patches in postmenopausal women, both types delivered similar total drug exposure over 72 hours, but the matrix patches with a penetration enhancer (lauric acid) produced more stable plasma concentrations, with less fluctuation over the wearing period.⁶ Interestingly, the same patients who were poor absorbers with one matrix patch were also poor absorbers with another matrix patch, but that pattern did not carry over to the reservoir type. This suggests that individual skin characteristics interact differently with each patch design, which is something prescribers rarely account for.

Why Heat Is a Serious Concern

One of the most underappreciated risks of transdermal patches is their sensitivity to temperature. Elevated skin temperature increases drug permeation, and the effect is not trivial. In studies of fentanyl patches, raising skin temperature from the normal surface temperature of about 32°C to 40°C doubled the permeation rate over the first 24 hours in both reservoir and matrix designs.⁷ Separate laboratory testing confirmed that a temperature increase from 32°C to 42°C resulted in a roughly two-fold increase in fentanyl flux, with the magnitude depending on when heat was applied and how long it lasted.⁸

In a clinical pharmacokinetic study, applying controlled heat to fentanyl patches in the first four hours produced peak blood concentrations almost three times higher than patches worn without heat, with correspondingly higher total drug exposure during that window.⁹ For a potent opioid like fentanyl, tripling the early blood concentration is not a minor inconvenience; it is a potentially life-threatening overdose scenario. Hot baths, saunas, heating pads, electric blankets, high fevers, and even vigorous exercise that raises local skin temperature can all produce this effect. This applies broadly to transdermal systems, not just fentanyl.¹⁰

Patients wearing any transdermal patch should avoid direct heat exposure at the patch site. This is included in prescribing information but often gets lost in the shuffle of a busy clinic visit. If you use a fentanyl or buprenorphine patch, keeping the patch away from heating pads and being cautious about hot tubs is not a suggestion from an overcautious pharmacist; it is a clinically documented safety issue.

Where You Place the Patch Matters

Not all skin is equal when it comes to drug absorption. The stratum corneum varies in thickness across the body, and so does the density of hair follicles, blood flow, and local lipid composition. Studies of percutaneous absorption at different body sites have consistently shown that the head, neck, and genital regions absorb chemicals most readily, while the trunk, back, and thighs absorb less.¹¹

This is why patch instructions specify application sites. Fentanyl patches, for instance, are meant for the upper arm, chest, back, or flank, not the wrist or neck where absorption could be unpredictably high. Nicotine patches are typically placed on the upper body or upper arm. Switching to a different site with each new patch is standard guidance, both to reduce local skin irritation and to avoid applying a patch to skin that has become sensitized from repeated use.

Skin hydration also plays a role. Moist or occluded skin absorbs drugs faster than dry skin, which is partly why the patch itself creates a favorable environment for absorption: by covering the skin, it traps moisture and increases local hydration. But excessive sweating can undermine the adhesive that holds the patch in place, creating a practical tradeoff between the moisture that aids absorption and the moisture that makes the patch fall off.

Skin Reactions and Adhesion Problems

Skin irritation is the most common side effect of transdermal patches. The irritation can be straightforward contact dermatitis from the adhesive or the occlusion itself, or it can progress to true allergic contact dermatitis triggered by the drug, the adhesive, or a penetration enhancer in the formulation. Patches create conditions that are, frankly, ideal for sensitization: they occlude the skin, keep the allergen in prolonged contact, and often go on the same general body region repeatedly.¹²

The adhesive itself is a surprisingly tricky engineering challenge. Most pressure-sensitive adhesives were developed for dry conditions, and skin is not a dry surface. Sweat, humidity, and even bathing can cause patches to peel or lose contact, which disrupts drug delivery and frustrates patients.¹³ Recent research has focused on amphiphilic adhesive strategies, where the adhesive is designed to actually activate or strengthen in the presence of water rather than losing grip.¹⁴ Integrating both pharmaceutical function and reliable adhesion into one platform remains an active area of development.

If a patch repeatedly falls off or causes irritation, the practical consequence is that the patient stops using it or uses it incorrectly. This is not a trivial cosmetic concern; it directly undermines the therapeutic purpose of the device.

How Patches Affect Patient Adherence

One of the most consistently observed benefits of transdermal patches is improved medication adherence. Remembering to take pills multiple times a day is harder than it sounds, especially for elderly patients managing several conditions simultaneously. A patch that gets changed once every three or seven days removes much of that cognitive burden.

In a study of patients with osteoarthritis pain, those using a transdermal buprenorphine patch scored significantly higher on adherence measures than patients taking oral opioids like co-codamol or tramadol. The patch group started at medium adherence and stayed there, while both oral groups fell into the low-adherence category.¹⁵ In Alzheimer’s disease, where patients often have difficulty managing complex medication regimens, switching from oral capsules to a transdermal patch was the single most effective intervention physicians used to improve adherence. The share of patients using patches jumped from about 6% at baseline to nearly 65% at the three-month follow-up, and patients using patches were significantly more likely to comply than those on oral formulations.¹⁶

The adherence advantage has particular value in conditions where steady blood drug levels matter. A patient with Parkinson’s disease who misses a dose of oral levodopa might experience sudden motor fluctuations, while a rotigotine patch delivers its dopamine agonist continuously. For nicotine replacement, the patch’s steady delivery helps manage cravings without the spikes and drops that come with gum or lozenges.

Microneedles and Active Enhancement Technologies

The traditional limitation of transdermal delivery is that only small, lipophilic, potent molecules can passively cross the skin. That rules out a huge number of drugs, including most proteins, peptides, and large hydrophilic molecules. Several technologies aim to overcome this limitation by physically disrupting the stratum corneum rather than relying on passive diffusion alone.

Dissolving microneedles are among the most promising approaches. These are tiny needle-like projections, typically a few hundred micrometers long, made from biocompatible materials that dissolve after insertion into the skin. Because they physically pierce the stratum corneum without reaching the nerve-rich deeper layers, they are essentially painless. Research has shown that drug molecules can be encapsulated within the microneedle shafts for rapid bolus delivery or within the backing material for sustained release over hours to days.¹⁷ Insulin delivery through dissolving microneedle arrays has produced measurable blood sugar lowering effects in animal studies, which is relevant because insulin is far too large to cross intact skin passively.¹⁸

Other active enhancement strategies use physical energy to push drugs through skin. Iontophoresis applies a low electrical current to drive charged drug molecules across the skin barrier. Sonophoresis uses low-frequency ultrasound, where the primary mechanism involves cavitation: tiny gas bubbles form and collapse in the coupling medium, temporarily disrupting the lipid structure of the stratum corneum.¹⁹ When iontophoresis and sonophoresis are combined, the enhancement effect is greater than either technique alone, broadening the range of deliverable drugs to include hydrophilic compounds and some biologics.²⁰

Smart Patches That Sense and Respond

The frontier of transdermal technology is the closed-loop system: a patch that not only delivers a drug but also monitors a biomarker and adjusts delivery accordingly. Diabetes management is the most active target for this approach, since the disease requires constant glucose monitoring coupled with insulin dosing.

A recently developed prototype combines a dissolving microneedle array with both insulin delivery and glucose sensing in one device. The system uses a hydrogel layer for controlled insulin release and a sponge microneedle base with embedded silver nanoparticles for antibacterial protection. In testing, it released over 83% of its insulin within 24 hours and controlled blood glucose for more than 8 hours. The glucose-sensing component responded to changes in blood sugar within 10 minutes through a visible color change, providing real-time feedback without an electronic sensor.²¹

This is still lab-stage work, and the gap between a functional prototype and a commercial medical device is enormous. Regulatory approval for a combination product that both delivers a drug and acts as a diagnostic device involves meeting requirements from multiple regulatory pathways simultaneously. Manufacturing at scale, maintaining sterility, ensuring consistent microneedle geometry across millions of units, and proving long-term stability are all unsolved engineering challenges. But the direction is clear: patches are evolving from passive drug-delivery vehicles into active therapeutic platforms.

Practical Tips for Getting the Most From a Patch

If you use or are prescribed a transdermal patch, several practical details can make a real difference in how well it works:

Site rotation: Apply each new patch to a different area within the approved zone. This reduces cumulative skin irritation and prevents localized sensitization.
Clean, dry, hairless skin: Hair follicles can interfere with adhesion, and moisture underneath the patch can cause it to peel. If hair needs to be removed, clip it rather than shaving, since a razor creates micro-abrasions that increase drug absorption unpredictably.
Avoid heat sources: Keep the patch site away from heating pads, hot water bottles, saunas, and prolonged direct sun exposure. Even a high fever can raise skin temperature enough to affect delivery.
Press firmly: After applying the patch, press it down with your palm for about 30 seconds. This improves contact between the adhesive and the skin surface, which is crucial for consistent drug transfer.
Dispose carefully: Used patches still contain residual drug. Fentanyl patches in particular retain enough active drug after use to be dangerous if a child or pet gets hold of one. Fold the used patch in half with the sticky sides together and follow your pharmacy’s disposal instructions.

Manufacturing Complexity Behind a Simple-Looking Product

A transdermal patch looks deceptively simple: a thin, flat, skin-colored square you stick on and forget. Behind that simplicity is a manufacturing process that has to control drug content uniformity across the patch area, adhesive coating thickness, release-liner peel properties, and long-term stability under storage conditions. The drug, adhesive, enhancers, and backing material all interact, and small changes in any component can shift the drug release profile.

Regulatory oversight of patch manufacturing reflects this complexity. The FDA treats transdermal systems as combination products that must meet both drug and device standards. Industry guidelines have evolved to incorporate quality-by-design principles and process analytical technologies that allow manufacturers to monitor critical parameters in real time during production rather than relying solely on end-product testing.²² One issue that has received increasing attention is residual drug: after a patch has been worn for its full intended duration, a significant amount of drug often remains in the system. For potent drugs, this residual content represents both a waste of expensive active ingredient and a post-use safety hazard, especially for fentanyl patches that may still contain milligram quantities of drug after removal.

Generic transdermal patches face an additional hurdle. Because the formulation and adhesive directly affect drug delivery, a generic patch cannot simply match the active ingredient and dose; it must demonstrate equivalent pharmacokinetic performance to the brand-name product. This is harder to do than for a generic tablet, where dissolution in stomach acid is a relatively straightforward test. For patches, in vitro release testing and in vivo bioequivalence studies both play a role, and correlating the two remains an area of active research and regulatory discussion.